Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION: UGN-102 in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550Phase 3Active, not recruiting
- Sponsor
- UroGen Pharma
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- DNA Intercalators/Alkylators, Hydrogel Systems
- Countries
- 10
01
Overview
A Phase 3 trial of zusduri in bladder cancer, sponsored by UroGen Pharma. Started Mar 2022; status: active, not recruiting.
02
Drugs
zusduri
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05243550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243550.